Trial
NCT03392064
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Small Cell Lung Cancer
Intervention
AMG 119
Why stopped
Study on enrollment hold, may potentially resume. No active subjects on trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-15